apolipoproteins b

Summary

Summary: Structural proteins of chylomicrons, VLDL; and LDL. They are important in the secretion and transport of these LIPOPROTEINS and function as recognition signals for binding and internalization of LDL particles by the LDL receptor (RECEPTORS, LDL). Atherosclerotic patients show high levels of Apo-B in the blood while in the case of ABETALIPOPROTEINEMIA they are not detectable in serum.

Top Publications

  1. ncbi High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study
    G Walldius
    Astra Zeneca, Mölndal and King Gustaf V Research Institute, Karolinska Institute, Stockholm, Sweden
    Lancet 358:2026-33. 2001
  2. doi Non-high-density lipoprotein cholesterol versus apolipoprotein B in cardiovascular risk stratification: do the math
    Vimal Ramjee
    J Willis Hurst Internal Medicine Residency, Emory University School of Medicine, Atlanta, GA 30303, USA
    J Am Coll Cardiol 58:457-63. 2011
  3. ncbi Apolipoprotein B and apolipoprotein A-I: risk indicators of coronary heart disease and targets for lipid-modifying therapy
    G Walldius
    King Gustaf V Research Institute and Karolinska Institute, Stockholm, Sweden
    J Intern Med 255:188-205. 2004
  4. ncbi Non-high-density lipoprotein cholesterol and apolipoprotein B in the prediction of coronary heart disease in men
    Tobias Pischon
    Department of Nutrition, Harvard School of Public Health, Boston, Massachusetts, USA
    Circulation 112:3375-83. 2005
  5. ncbi RNAi-mediated gene silencing in non-human primates
    Tracy S Zimmermann
    Alnylam Pharmaceuticals Inc, 300 Third Street, Cambridge, Massachusetts 02142, USA
    Nature 441:111-4. 2006
  6. ncbi The apoB/apoA-I ratio: a strong, new risk factor for cardiovascular disease and a target for lipid-lowering therapy--a review of the evidence
    G Walldius
    King Gustaf V Research Institute, Karolinska Institute, Stockholm, Sweden
    J Intern Med 259:493-519. 2006
  7. ncbi Microsomal triglyceride transfer protein and its role in apoB-lipoprotein assembly
    M Mahmood Hussain
    Department of Anatomy, SUNY Downstate Medical Center, 450 Clarkson Avenue, Brooklyn, NY 11203, USA
    J Lipid Res 44:22-32. 2003
  8. ncbi Measurement and meaning of apolipoprotein AI and apolipoprotein B plasma levels
    S Marcovina
    Department of Medicine, University of Washington, Seattle, WA, USA
    J Intern Med 259:437-46. 2006
  9. ncbi Apolipoprotein B and cardiovascular disease risk: position statement from the AACC Lipoproteins and Vascular Diseases Division Working Group on Best Practices
    John H Contois
    Maine Standards Company, Windham, ME 04062, USA
    Clin Chem 55:407-19. 2009
  10. ncbi Prognostic value of apolipoprotein B and A-I in the prediction of myocardial infarction in middle-aged men and women: results from the MONICA/KORA Augsburg cohort study
    Christa Meisinger
    Central Hospital of Augsburg, MONICA KORA Myocardial Infarction Registry, Augsburg, Germany
    Eur Heart J 26:271-8. 2005

Research Grants

  1. Development of CNS-targeted AAV vectors
    Miguel Esteves; Fiscal Year: 2009
  2. MOLECULAR MECHANISMS OF OXIDATION OF LDL
    Sampath Parthasarathy; Fiscal Year: 1999
  3. APOLIPOPROTEIN B48 AND LIPOPROTEIN METABOLISM
    Lawrence Chan; Fiscal Year: 2002
  4. APOLIPOPROTEIN B48 AND LIPOPROTEIN METABOLISM
    Lawrence Chan; Fiscal Year: 2000
  5. APOLIPOPROTEIN B48 AND LIPOPROTEIN METABOLISM
    Lawrence Chan; Fiscal Year: 2003
  6. APOLIPOPROTEIN B48 AND LIPOPROTEIN METABOLISM
    Lawrence Chan; Fiscal Year: 2002
  7. APOLIPOPROTEIN B48 AND LIPOPROTEIN METABOLISM
    Lawrence Chan; Fiscal Year: 2004
  8. APOLIPOPROTEIN B48 AND LIPOPROTEIN METABOLISM
    Lawrence Chan; Fiscal Year: 2001
  9. NUTRITIONAL EFFECTS OF SUGARS ON LIVER LIPIDS
    CHARLES SPARKS; Fiscal Year: 1990
  10. ASSEMBLY OF NASCENT PLASMA LIPOPROTEINS BY HEPATOCYTES
    Robert Hamilton; Fiscal Year: 1991

Detail Information

Publications257 found, 100 shown here

  1. ncbi High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study
    G Walldius
    Astra Zeneca, Mölndal and King Gustaf V Research Institute, Karolinska Institute, Stockholm, Sweden
    Lancet 358:2026-33. 2001
    ..We also aimed to establish whether apoB and apoA-I add further information about risk of fatal myocardial infarction to that obtained with total cholesterol, triglycerides, and LDL-cholesterol...
  2. doi Non-high-density lipoprotein cholesterol versus apolipoprotein B in cardiovascular risk stratification: do the math
    Vimal Ramjee
    J Willis Hurst Internal Medicine Residency, Emory University School of Medicine, Atlanta, GA 30303, USA
    J Am Coll Cardiol 58:457-63. 2011
    ..The purpose of this review is to assess the performance of these parameters in this context and to discuss the considerations of implementation into clinical practice...
  3. ncbi Apolipoprotein B and apolipoprotein A-I: risk indicators of coronary heart disease and targets for lipid-modifying therapy
    G Walldius
    King Gustaf V Research Institute and Karolinska Institute, Stockholm, Sweden
    J Intern Med 255:188-205. 2004
    ..Measurement of these apolipoproteins could improve cardiovascular risk prediction...
  4. ncbi Non-high-density lipoprotein cholesterol and apolipoprotein B in the prediction of coronary heart disease in men
    Tobias Pischon
    Department of Nutrition, Harvard School of Public Health, Boston, Massachusetts, USA
    Circulation 112:3375-83. 2005
    ....
  5. ncbi RNAi-mediated gene silencing in non-human primates
    Tracy S Zimmermann
    Alnylam Pharmaceuticals Inc, 300 Third Street, Cambridge, Massachusetts 02142, USA
    Nature 441:111-4. 2006
    ..Our findings show clinically relevant RNAi-mediated gene silencing in non-human primates, supporting RNAi therapeutics as a potential new class of drugs...
  6. ncbi The apoB/apoA-I ratio: a strong, new risk factor for cardiovascular disease and a target for lipid-lowering therapy--a review of the evidence
    G Walldius
    King Gustaf V Research Institute, Karolinska Institute, Stockholm, Sweden
    J Intern Med 259:493-519. 2006
    ..Guidelines should be developed in order to recognize the important clinical risk information embedded in the apoB/apoA-I ratio...
  7. ncbi Microsomal triglyceride transfer protein and its role in apoB-lipoprotein assembly
    M Mahmood Hussain
    Department of Anatomy, SUNY Downstate Medical Center, 450 Clarkson Avenue, Brooklyn, NY 11203, USA
    J Lipid Res 44:22-32. 2003
    ..However, specific steps in lipoprotein assembly that require apoB-MTP binding have not been identified. ApoB-MTP binding may be important for the prevention of degradation and lipidation of nascent apoB...
  8. ncbi Measurement and meaning of apolipoprotein AI and apolipoprotein B plasma levels
    S Marcovina
    Department of Medicine, University of Washington, Seattle, WA, USA
    J Intern Med 259:437-46. 2006
    ..Assessment of apolipoprotein levels is an aid to risk prediction and can be useful in tailoring treatment...
  9. ncbi Apolipoprotein B and cardiovascular disease risk: position statement from the AACC Lipoproteins and Vascular Diseases Division Working Group on Best Practices
    John H Contois
    Maine Standards Company, Windham, ME 04062, USA
    Clin Chem 55:407-19. 2009
    ..Low-density lipoprotein cholesterol (LDL-C) has been the cornerstone measurement for assessing cardiovascular risk for nearly 20 years...
  10. ncbi Prognostic value of apolipoprotein B and A-I in the prediction of myocardial infarction in middle-aged men and women: results from the MONICA/KORA Augsburg cohort study
    Christa Meisinger
    Central Hospital of Augsburg, MONICA KORA Myocardial Infarction Registry, Augsburg, Germany
    Eur Heart J 26:271-8. 2005
    ..To investigate the association between apolipoprotein B (apoB), A-I (apoA-I), the apoB/apoA-I ratio, and the incidence of coronary events...
  11. ncbi Microsomal triglyceride transfer protein promotes the secretion of Xenopus laevis vitellogenin A1
    Jeremy A Sellers
    Department of Pathology, Wake Forest University School of Medicine Winston Salem, North Carolina 27157 1040, USA
    J Biol Chem 280:13902-5. 2005
    ..These studies demonstrate that the biogenesis of Vtg is MTP-dependent and that MTP is the likely ancestral member of the LLTP gene family...
  12. pmc Monogenic hypercholesterolemia: new insights in pathogenesis and treatment
    Daniel J Rader
    Department of Medicine and Center for Experimental Therapeutics, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA
    J Clin Invest 111:1795-803. 2003
  13. ncbi Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B, and HDL density subfractions: The Atherosclerosis Risk in Communities (ARIC) Study
    A R Sharrett
    Epidemiology and Biometry Program, National Heart, Lung, and Blood Institute, Bethesda, MD, USA
    Circulation 104:1108-13. 2001
    ..CONCLUSIONS: Optimal LDL-C values are <100 mg/dL in both women and men. LDL-C, HDL-C, TG, and Lp(a), without additional apolipoproteins or lipid subfractions, provide substantial CHD prediction, with much higher RR in women than men...
  14. pmc Serum apolipoprotein AI and B are stronger biomarkers of diabetic retinopathy than traditional lipids
    Muhammad Bayu Sasongko
    Centre for Eye Research Australia, Royal Victorian Eye and Ear Hospital, University of Melbourne, Melbourne, Victoria, Australia
    Diabetes Care 34:474-9. 2011
    ..To describe and compare the associations of serum lipoproteins and apolipoproteins with diabetic retinopathy...
  15. ncbi Variants of the microsomal triglyceride transfer protein gene are associated with plasma cholesterol levels and body mass index
    Helena Ledmyr
    King Gustaf V Research Institute, Karolinska Hospital, SE 171 76, Stockholm, Sweden
    J Lipid Res 43:51-8. 2002
    ..This may, in turn, have implications for genetic regulation of cardiovascular risk factors...
  16. ncbi Cholesterol-lowering effects of rosuvastatin compared with atorvastatin in patients with type 2 diabetes -- CORALL study
    B H R Wolffenbuttel
    University Medical Centre, Groningen, The Netherlands
    J Intern Med 257:531-9. 2005
    ..To compare the efficacy of the newest cholesterol-lowering drug, rosuvastatin (RSV) with atorvastatin (ATV) in subjects with type 2 diabetes...
  17. ncbi Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs
    Jürgen Soutschek
    Alnylam Europe AG, Fritz Hornschuch Str 9, 95326 Kulmbach, Germany
    Nature 432:173-8. 2004
    ..These findings demonstrate the therapeutic potential of siRNAs for the treatment of disease...
  18. doi Genetic variants associated with myocardial infarction risk factors in over 8000 individuals from five ethnic groups: The INTERHEART Genetics Study
    Sonia S Anand
    Population Health Research Institute, Hamilton Health Sciences, Ontario, Canada
    Circ Cardiovasc Genet 2:16-25. 2009
    ..Myocardial infarction (MI) is a leading cause of death globally, but specific genetic variants that influence MI and MI risk factors have not been assessed on a global basis...
  19. pmc Cellular determinants of hepatitis C virus assembly, maturation, degradation, and secretion
    Pablo Gastaminza
    The Scripps Research Institute, Maildrop SBR 10, 10550 North Torrey Pines Road, La Jolla, CA 92037, USA
    J Virol 82:2120-9. 2008
    ..These results suggest that by coopting the VLDL assembly, maturation, degradation, and secretory machinery of the cell, HCV acquires its hepatocyte tropism and, by mimicry, its tendency to persist...
  20. doi Apolipoprotein measurements: is more widespread use clinically indicated?
    Michael H Davidson
    Preventive Cardiology Center, University of Chicago Pritzker School of Medicine, Chicago, Illinois, USA
    Clin Cardiol 32:482-6. 2009
    ....
  21. ncbi The role of the microsomal triglygeride transfer protein in abetalipoproteinemia
    N Berriot-Varoqueaux
    U327 Institut National de la Santé et de la Recherche Médicale, Faculte de Medecine Xavier Bichat, Université de Paris 7 Denis Diderot, 75870 Paris, France
    Annu Rev Nutr 20:663-97. 2000
    ..Unless treated, abetalipoproteinemic subjects develop gastrointestinal, neurological, ophthalmological, and hematological abnormalities...
  22. ncbi Efficacy and safety of mipomersen, an antisense inhibitor of apolipoprotein B, in hypercholesterolemic subjects receiving stable statin therapy
    Fatima Akdim
    Department of Vascular Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
    J Am Coll Cardiol 55:1611-8. 2010
    ..The aim of this study was to evaluate the efficacy and safety of mipomersen in hypercholesterolemic subjects taking stable statin therapy...
  23. ncbi Overexpression of apolipoprotein B in the heart impedes cardiac triglyceride accumulation and development of cardiac dysfunction in diabetic mice
    Lars Bo Nielsen
    Department of Clinical Biochemistry KB3011, Rigshospitalet, University of Copenhagen, Blegdamsvej 9, DK 2100 Copenhagen, Denmark
    J Biol Chem 277:27014-20. 2002
    ..The findings suggest that triglyceride accumulation in the heart is important for development of diabetic cardiomyopathy in mice, and that lipoprotein formation by cardiomyocytes plays an integrated role in cardiac lipid metabolism...
  24. ncbi Secretion of hepatocyte apoB is inhibited by the flavonoids, naringenin and hesperetin, via reduced activity and expression of ACAT2 and MTP
    L J Wilcox
    Departments of Medicine and Biochemistry and The John P. Robarts Research Institute, 4-16, University of Western Ontario, 100 Perth Drive, London, Ontario N6A 5K8, Canada
    J Lipid Res 42:725-34. 2001
    ..Together with an enhanced expression of the LDL receptor, these mechanisms may explain the hypocholesterolemic properties of the citrus flavonoids...
  25. doi Carotid intima-media thickness and apolipoprotein B/apolipoprotein A-I ratio in middle-aged patients with Type 2 diabetes
    E M Dahlén
    Department of Medical and Health Sciences, Linkoping University, Linkoping, Sweden
    Diabet Med 26:384-90. 2009
    ..To explore the association between carotid intima-media thickness (IMT) and the apolipoprotein B (apoB)/apolipoprotein A-I (apoA-I) ratio compared with conventional lipids in middle-aged patients with Type 2 diabetes...
  26. ncbi Clinical utility of different lipid measures for prediction of coronary heart disease in men and women
    Erik Ingelsson
    Framingham Heart Study, 73 Mount Wayte Ave, Suite 2, Framingham, MA 01702 5803
    JAMA 298:776-85. 2007
    ..Evidence is conflicting regarding the performance of apolipoproteins vs traditional lipids for predicting coronary heart disease (CHD) risk...
  27. ncbi Impaired recycling of apolipoprotein E4 is associated with intracellular cholesterol accumulation
    Joerg Heeren
    Institute for Biochemistry and Molecular Biology II Molecular Cell Biology and Department of Internal Medicine, University Hospital Eppendorf, Martinistrasse 52, D 20246 Hamburg, Germany
    J Biol Chem 279:55483-92. 2004
    ..These studies provide initial evidence that impaired recycling of apoE4 could interfere with intracellular cholesterol transport and contribute to the pathophysiological lipoprotein profile observed in apoE4 homozygotes...
  28. ncbi The structure of vitellogenin provides a molecular model for the assembly and secretion of atherogenic lipoproteins
    C J Mann
    MRC Molecular Medicine Group, Imperial College School of Medicine, London W12 ONN, UK
    J Mol Biol 285:391-408. 1999
    ..The structural and functional evolution of the VTGs provides a unifying scheme for the invertebrate origins of the major vertebrate lipid transport system...
  29. ncbi Fenofibrate therapy ameliorates fasting and postprandial lipoproteinemia, oxidative stress, and the inflammatory response in subjects with hypertriglyceridemia and the metabolic syndrome
    Robert S Rosenson
    Division of Cardiovascular Medicine, University of Michigan, Domino s Farms, 24 Frank Lloyd Wright Dr, Lobby A, Ann Arbor, MI 48106 0736, USA
    Diabetes Care 30:1945-51. 2007
    ..The aim of this study was to determine the effects of fenofibrate (160 mg/day) on fasting and postprandial lipoproteins, oxidized fatty acids, and inflammatory mediators in subjects with hypertriglyceridemia and the metabolic syndrome...
  30. ncbi Concordance/discordance between plasma apolipoprotein B levels and the cholesterol indexes of atherosclerotic risk
    Allan D Sniderman
    Mike Rosenbloom Laboratory for Cardiovascular Research, McGill University Health Centre, Montreal, Quebec, Canada
    Am J Cardiol 91:1173-7. 2003
    ....
  31. ncbi Glycoprotein 330/low density lipoprotein receptor-related protein-2 mediates endocytosis of low density lipoproteins via interaction with apolipoprotein B100
    S Stefansson
    Biochemistry Department, J H Holland Laboratory, American Red Cross, Rockville, Maryland 20855, USA
    J Biol Chem 270:19417-21. 1995
    ..The results indicate that LRP-2 can function to mediate cellular endocytosis of LDL, leading to its degradation. LRP-2 represents the second member of the LDLR family identified as functioning in the catabolism of LDL...
  32. pmc Peripheral delivery of a CNS targeted, metalo-protease reduces aβ toxicity in a mouse model of Alzheimer's disease
    Brian Spencer
    Department of Neurosciences, University of California San Diego, La Jolla, California, United States of America
    PLoS ONE 6:e16575. 2011
    ..Thus, the addition of the ApoB transport domain to the secreted neprilysin generated a non-invasive therapeutic approach that may be a potential treatment in patients with AD...
  33. pmc The complete sequence and structural analysis of human apolipoprotein B-100: relationship between apoB-100 and apoB-48 forms
    C Cladaras
    EMBO J 5:3495-507. 1986
    ..These two messages may have resulted from differential splicing of the same primary apoB mRNA transcript...
  34. pmc Adiponectin reduces plasma triglyceride by increasing VLDL triglyceride catabolism
    Liping Qiao
    Graduate Center for Nutritional Sciences, University of Kentucky, Lexington, Kentucky, USA
    Diabetes 57:1824-33. 2008
    ..The main aims of this study are to investigate the effects of adiponectin on VLDL triglyceride (VLDL-TG) metabolism and the underlying mechanism...
  35. ncbi A Drosophila microsomal triglyceride transfer protein homolog promotes the assembly and secretion of human apolipoprotein B. Implications for human and insect transport and metabolism
    Jeremy A Sellers
    Department of Pathology, Wake Forest University School of Medicine, Winston Salem, North Carolina 27157 1040, USA
    J Biol Chem 278:20367-73. 2003
    ..We conclude that CG9342 and human MTP are orthologs that share only a subset of functions, consistent with known differences in intracellular and extracellular aspects of vertebrate and invertebrate lipid transport and metabolism...
  36. ncbi Diagnosis and treatment of apolipoprotein B dyslipoproteinemias
    Allan Sniderman
    Mike Rosenbloom Laboratory for Cardiovascular Research, McGill University Health Center, Room H7 22, Royal Victoria Hospital, 687 Pine Avenue West, Montreal, QC H3A 1A1, Canada
    Nat Rev Endocrinol 6:335-46. 2010
    ..Here, we review the diagnostic algorithm for apoB dyslipoproteinemias and provide, for the first time, a treatment plan on the basis of a reduction of atherogenic lipoprotein particles rather than plasma lipids...
  37. ncbi Modification of low-density lipoprotein by myeloperoxidase-derived oxidants and reagent hypochlorous acid
    Ernst Malle
    Medical University Graz, Center of Molecular Medicine, Institute of Molecular Biology and Biochemistry, Harrachgasse 21, A 8010 Graz, Austria
    Biochim Biophys Acta 1761:392-415. 2006
    ....
  38. ncbi Comparison of the associations of apolipoprotein B and low-density lipoprotein cholesterol with other cardiovascular risk factors in the Insulin Resistance Atherosclerosis Study (IRAS)
    Ken Williams
    Department of Medicine, University of Texas Health Science Center, San Antonio, USA
    Circulation 108:2312-6. 2003
    ..This study compares the associations of apolipoprotein B (apoB) and LDL cholesterol (LDLC) with a wide array of measures of these risk factors...
  39. doi Familial hypercholesterolemia: epidemiology, Neolithic origins and modern geographic distribution
    Khemanganee E Liyanage
    School of Pathology and Laboratory Medicine, University of Western Australia, Crawley, Western Australia
    Crit Rev Clin Lab Sci 48:1-18. 2011
    ....
  40. ncbi Phenotypic expression of familial hypobetalipoproteinemia in three kindreds with mutations of apolipoprotein B gene
    P Tarugi
    Dipartimento di Scienze Biomediche, Universita di Modena e Reggio Emilia, Via Campi 287, I 41100 Modena, Italy
    J Lipid Res 42:1552-61. 2001
    ....
  41. ncbi Subendothelial retention of atherogenic lipoproteins in early atherosclerosis
    Kristina Skålén
    Wallenberg Laboratory for Cardiovascular Research, Goteborg University, Göteborg S 4345, Sweden
    Nature 417:750-4. 2002
    ..We conclude that subendothelial retention of apoB100-containing lipoprotein is an early step in atherogenesis...
  42. doi Apolipoprotein B/A-I and total cholesterol/high-density lipoprotein cholesterol ratios both predict cardiovascular events in the general population independently of nonlipid risk factors, albuminuria and C-reactive protein
    P J W H Kappelle
    Departments of Endocrinology, University Medical Center Groningen and University of Groningen, Groningen, The Netherlands
    J Intern Med 269:232-42. 2011
    ..We compared the strength of these ratios with first MACE in the general population and determined whether these associations remain when taking account of these risk markers...
  43. ncbi Ability of traditional lipid ratios and apolipoprotein ratios to predict cardiovascular risk in people with type 2 diabetes
    M R Taskinen
    Department of Medicine, Division of Cardiology, Helsinki University Central Hospital, Biomedicum, Haartmaninkatu 8, Helsinki, Finland
    Diabetologia 53:1846-55. 2010
    ....
  44. doi Mutation detection rate and spectrum in familial hypercholesterolaemia patients in the UK pilot cascade project
    A Taylor
    Great Ormond Street Hospital for Children, London, UK
    Clin Genet 77:572-80. 2010
    ..Even in subjects with a low clinical suspicion of FH, and in those of Indian origin, mutation testing has an acceptable detection rate...
  45. ncbi The apoB/apoA-I ratio is better than the cholesterol ratios to estimate the balance between plasma proatherogenic and antiatherogenic lipoproteins and to predict coronary risk
    Goran Walldius
    King Gustaf V Research Institute, Karolinska Institute, Stockholm, Sweden
    Clin Chem Lab Med 42:1355-63. 2004
    ..Moreover, we examined whether any lipids, lipoproteins or cholesterol ratios add significant predictive information beyond that provided by the apoB/apoA-I ratio...
  46. ncbi Effect of the microsomal triglyceride transfer protein -493 G/T polymorphism and type 2 diabetes mellitus on LDL subfractions
    S P L Chen
    Department of Medicine, Queen Mary Hospital, University of Hong Kong, Pokfulam Road, Hong Kong
    Atherosclerosis 167:287-92. 2003
    ..01). In conclusion, the -493 G/T polymorphism only has a minor effect on LDL subfraction pattern in Chinese and the effect is only apparent in the presence of type 2 diabetes...
  47. ncbi Very low density lipoprotein metabolism and plasma adiponectin as predictors of high-density lipoprotein apolipoprotein A-I kinetics in obese and nonobese men
    Dick C Chan
    School of Medicine and Pharmacology, University of Western Australia, Royal Perth Hospital, Perth, Western Australia 6847, Australia
    J Clin Endocrinol Metab 94:989-97. 2009
    ..The mechanisms regulating apoA-I catabolism may relate to alterations in very low density lipoprotein (VLDL) metabolism and plasma adiponectin and serum amyloid A protein (SAA) concentrations...
  48. ncbi Apolipoprotein B versus non-high-density lipoprotein cholesterol: and the winner is
    Allan D Sniderman
    Circulation 112:3366-7. 2005
  49. ncbi Apolipoprotein B, non-HDL cholesterol and LDL cholesterol for identifying individuals at increased cardiovascular risk
    S Holewijn
    Division of Vascular Medicine, Department of General Internal Medicine, Radboud University, Nijmegen Medical Centre, Nijmegen, The Netherlands
    J Intern Med 268:567-77. 2010
    ....
  50. pmc Effect of apolipoprotein-B synthesis inhibition on liver triglyceride content in patients with familial hypercholesterolemia
    Maartje E Visser
    Department of Vascular Medicine, Academic Medical Center Amsterdam, The Netherlands
    J Lipid Res 51:1057-62. 2010
    ..Future studies evaluating the effects of long-term use of mipomersen reaching more profound reductions in apoB are required prior to broader use of this compound...
  51. doi When is equal not equal?
    Allan D Sniderman
    Mike Rosenbloom Laboratory for Cardiovascular Research, McGill University Health Centre, Room H7 22, Royal Victoria Hospital, 687 Pine Avenue West, Montreal, Quebec H3A 1A1, Canada
    J Clin Lipidol 4:83-8. 2010
    ..Our objective should be to learn how to combine the information from parameters rather than eliminate them and we need to focus on evaluation of risk in individuals and not just groups...
  52. ncbi Phospholipid transfer activity of microsomal triacylglycerol transfer protein is sufficient for the assembly and secretion of apolipoprotein B lipoproteins
    Paul Rava
    Department of Anatomy and Cell Biology, SUNY Downstate Medical Center, Brooklyn, New York 11203, USA
    J Biol Chem 281:11019-27. 2006
    ..Identification of MTP inhibitors, which selectively affect transfer of a specific lipid class, may have therapeutic potential...
  53. ncbi Structural biology. LDL receptor's beta-propeller displaces LDL
    Thomas L Innerarity
    Gladstone Institute of Cardiovascular Disease, San Francisco, CA 94110, USA
    Science 298:2337-9. 2002
  54. ncbi The hepatitis B virus X protein inhibits secretion of apolipoprotein B by enhancing the expression of N-acetylglucosaminyltransferase III
    Sung Koo Kang
    National Research Laboratory for Glycobiology, and Department of Biochemistry and Molecular Biology, College of Oriental Medicine, Dongguk University, Sukjang dong 707, Kyungju City, Kyungbuk 780 714, Korea
    J Biol Chem 279:28106-12. 2004
    ....
  55. ncbi Hepatic fatty acid synthesis is suppressed in mice with fatty livers due to targeted apolipoprotein B38.9 mutation
    Xiaobo Lin
    Division of Atherosclerosis, Nutrition and Lipid Research, Department of Medicine, Washington University School of Medicine, St Louis, MO 63110, USA
    Arterioscler Thromb Vasc Biol 22:476-82. 2002
    ..The signals mediating suppression of FAS and SREBP-1c levels remain to be identified...
  56. ncbi Comparison of apolipoprotein B metabolism in familial defective apolipoprotein B and heterogeneous familial hypercholesterolemia
    Dairena Gaffney
    Department of Pathological Biochemistry, Glasgow Royal Infirmary, North Glasgow Hospitals University NHS Trust, 4th Floor, Queen Elizabeth Building, Alexandra Parade, Glasgow G31 2ER, Scotland, UK
    Atherosclerosis 162:33-43. 2002
    ..We conclude that disturbances in IDL metabolism provide the basis for understanding why FDB is less severe than FH. Our findings suggest that an apoB-LDL receptor interaction is important in the IDL to LDL conversion...
  57. ncbi APOLIPOPROTEIN B: mRNA editing, lipoprotein assembly, and presecretory degradation
    N O Davidson
    Departments of Medicine and Molecular Biology and Pharmacology, Washington University Medical School, St Louis, Missouri 63110, USA
    Annu Rev Nutr 20:169-93. 2000
    ..Although control of lipid secretion in vivo is primarily achieved at the level of lipoprotein particle size, regulation of apoB production by presecretory degradation may be relevant in some dyslipidemic states...
  58. ncbi Management of non-high-density lipoprotein abnormalities
    Robert S Rosenson
    Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, State University of New York, Downstate, Brooklyn, NY, USA
    Atherosclerosis 207:328-35. 2009
    ..Improvement in lipid control and reduction in atherogenic risk could be anticipated to translate to benefits in clinical outcomes...
  59. ncbi Can measurement of serum apolipoprotein B replace the lipid profile monitoring of patients with lipoprotein disorders?
    Saman Miremadi
    Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, V6Z 1Y6, Canada
    Clin Chem 48:484-8. 2002
    ..Considerable evidence indicates that apolipoprotein B (apo B) is a better index of reaching or not reaching treatment targets than total or LDL cholesterol...
  60. ncbi Nascent lipidated apolipoprotein B is transported to the Golgi as an incompletely folded intermediate as probed by its association with network of endoplasmic reticulum molecular chaperones, GRP94, ERp72, BiP, calreticulin, and cyclophilin B
    Jianying Zhang
    Department of Physiology and Biophysics, Center for Advanced Biomedical Research, Boston University School of Medicine, Boston, Massachusetts 02118, USA
    J Biol Chem 278:7459-68. 2003
    ....
  61. ncbi Structure of apolipoprotein B-100 in low density lipoproteins
    J P Segrest
    Department of Medicine, 630 Boshell Bldg, 3, UAB Medical Center, Birmingham, AL 35294 0012, USA
    J Lipid Res 42:1346-67. 2001
    ....
  62. pmc Identification of the low density lipoprotein receptor-binding site in apolipoprotein B100 and the modulation of its binding activity by the carboxyl terminus in familial defective apo-B100
    J Boren
    Gladstone Institute of Cardiovascular Disease, University of California, San Francisco, California 94141 9100, USA
    J Clin Invest 101:1084-93. 1998
    ..Moreover, the loss of arginine at this site destabilizes this interaction, resulting in receptor-binding defective LDL...
  63. pmc Nonsynonymous mutations within APOB in human familial hypobetalipoproteinemia: evidence for feedback inhibition of lipogenesis and postendoplasmic reticulum degradation of apolipoprotein B
    Shumei Zhong
    Department of Biochemistry, Microbiology and Immunology, Ottawa Institute of Systems Biology, University of Ottawa, Ottawa, Ontario K1H 8M5, Canada
    J Biol Chem 285:6453-64. 2010
    ..These results suggest that feedback inhibition of hepatic lipogenesis in conjunction with post-ER degradation of misfolded apoB proteins can contribute to reduce fat accumulation in the FHBL liver...
  64. ncbi Human apolipoprotein B: structure of carboxyl-terminal domains, sites of gene expression, and chromosomal localization
    T J Knott
    Science 230:37-43. 1985
    ..The apo-B100 gene is expressed primarily in liver and, to a lesser extent, in small intestine, but in no other tissues. The gene for apo-B100 is located in the p24 region (near the tip of the short arm) of chromosome 2...
  65. ncbi Overproduction of large VLDL particles is driven by increased liver fat content in man
    M Adiels
    Wallenberg Laboratory, Gothenburg University, Gothenburg, Sweden
    Diabetologia 49:755-65. 2006
    ..We determined whether hepatic fat content and plasma adiponectin concentration regulate VLDL(1) production...
  66. ncbi Triglycerides and small dense LDL: the twin Achilles heels of the Friedewald formula
    Allan D Sniderman
    Mike Rosenbloom Laboratory for Cardiovascular Research, McGill University Health Centre, McGill University, Montreal, Quebec, Canada
    Clin Biochem 36:499-504. 2003
  67. ncbi Paraoxonase-2 deficiency aggravates atherosclerosis in mice despite lower apolipoprotein-B-containing lipoproteins: anti-atherogenic role for paraoxonase-2
    Carey J Ng
    Department of Medicine, David Geffen School of Medicine, UCLA, Los Angeles, California 90095, USA
    J Biol Chem 281:29491-500. 2006
    ..These results demonstrate that PON2 plays a protective role in atherosclerosis...
  68. pmc New approaches to target microsomal triglyceride transfer protein
    Mohammed Mahmood Hussain
    Departments of Anatomy and Cell Biology, and Pediatrics, SUNY Downstate Medical Center, Brooklyn, New York 11203, USA
    Curr Opin Lipidol 19:572-8. 2008
    ..MTP inhibition increases plasma transaminases and tissue lipids, and therefore new approaches are needed to avoid them...
  69. pmc Hepatitis C virus production by human hepatocytes dependent on assembly and secretion of very low-density lipoproteins
    Hua Huang
    Department of Molecular Genetics, University of Texas Southwestern Medical Center, Dallas, TX 75390 9046, USA
    Proc Natl Acad Sci U S A 104:5848-53. 2007
    ..These results provide a possible explanation for the restriction of HCV production to the liver and suggest new cellular targets for treatment of HCV infection...
  70. ncbi Progress towards understanding the role of microsomal triglyceride transfer protein in apolipoprotein-B lipoprotein assembly
    D A Gordon
    Division of Metabolic and Cardiovascular Drug Discovery, Bristol Myers Squibb Pharmaceutical Research Institute, Princeton, NJ 08543, USA
    Biochim Biophys Acta 1486:72-83. 2000
    ..In addition, assembly of dense apolipoprotein B-48 containing lipoproteins has been observed in mouse liver in the absence of MTP. As a result of these new data, an updated model for the role of MTP in lipoprotein assembly is proposed...
  71. ncbi Fasting and postprandial overproduction of intestinally derived lipoproteins in an animal model of insulin resistance. Evidence that chronic fructose feeding in the hamster is accompanied by enhanced intestinal de novo lipogenesis and ApoB48-containing li
    Mehran Haidari
    Department of Laboratory Medicine and Pathobiology, Hospital for Sick Children, University of Toronto, Toronto, Ontario M5G 1X8, Canada
    J Biol Chem 277:31646-55. 2002
    ....
  72. ncbi Hepatocyte apoB-containing lipoprotein secretion is decreased by the grapefruit flavonoid, naringenin, via inhibition of MTP-mediated microsomal triglyceride accumulation
    Nica M Borradaile
    The Department of Medicine, The University of Western Ontario, London, Ontario, Canada
    Biochemistry 42:1283-91. 2003
    ..Taken together, our results indicate that naringenin inhibits the lipidation and subsequent secretion of apoB-containing lipoproteins primarily by limiting the accumulation of TG in the ER lumen, secondary to MTP inhibition...
  73. ncbi ApoB/ApoA1 ratio and subclinical atherosclerosis
    A Panayiotou
    Department of Biomedical Sciences, University of Cyprus, Nicosia, Cyprus
    Int Angiol 27:74-80. 2008
    ..The aim of this study was to test the hypothesis that ApoB/ApoA1 ratio is associated with early subclinical atherosclerosis as demonstrated by ultrasonic measurements...
  74. pmc MicroRNA-like off-target transcript regulation by siRNAs is species specific
    Julja Burchard
    Rosetta Inpharmatics LLC, Seattle, Washington 98109, USA
    RNA 15:308-15. 2009
    ..Therefore, siRNA therapeutics may trigger microRNA-like silencing of many unintended targets in vivo, and the potential toxicities caused by these off-target gene regulations cannot be accurately assessed in rodent models...
  75. ncbi Inhibition of net HepG2 cell apolipoprotein B secretion by the citrus flavonoid naringenin involves activation of phosphatidylinositol 3-kinase, independent of insulin receptor substrate-1 phosphorylation
    Nica M Borradaile
    Department of Medicine and the Robarts Research Institute, University of Western Ontario, London, Ontario, Canada
    Diabetes 52:2554-61. 2003
    ..Although this pathway may not regulate apoB secretion in primary hepatocytes, PI3K activation by this novel mechanism may explain the insulin-like effects of naringenin in vivo...
  76. ncbi Intracellular assembly of VLDL: two major steps in separate cell compartments
    S O Olofsson
    Department of Medical Biochemistry and the Wallenberg Laboratory for Cardiovascular Research, University of Goteborg, Goteborg, Sweden Sven Olof
    Trends Cardiovasc Med 10:338-45. 2000
    ..In the second step pre-VLDL is converted to bona fide VLDL in a smooth membrane compartment. This step depends on ADP-ribosylation factor 1 and its activation of phospholipase D...
  77. pmc Dynamic PolyConjugates for targeted in vivo delivery of siRNA to hepatocytes
    David B Rozema
    Mirus Bio Corporation, 505 South Rosa Road, Madison, WI 53719, USA
    Proc Natl Acad Sci U S A 104:12982-7. 2007
    ..Analyses of serum liver enzyme and cytokine levels in treated mice indicated that the siRNA Dynamic PolyConjugate was nontoxic and well tolerated...
  78. ncbi Association of C677T polymorphism in MTHFR gene, high homocysteine and low HDL cholesterol plasma values in heterozygous familial hypercholesterolemia
    Jose T Real
    Hospital Clinico Universitario, Department of Medicine, University of Valencia, Spain
    J Atheroscler Thromb 16:815-20. 2009
    ..to investigate the association of C677T polymorphism in the methylene tetrahydrofolate reductase (MTHFR) gene, homocysteine plasma values (Hcy), and plasma HDL cholesterol in heterozy-gous familial hypercholesterolemia (hFH)...
  79. ncbi Apolipoprotein B levels, APOB alleles, and risk of ischemic cardiovascular disease in the general population, a review
    Marianne Benn
    Department of Clinical Biochemistry KB3011, Section for Molecular Genetics, Rigshospitalet, Copenhagen University Hospital, Blegdamsvej 9, Copenhagen Ø, Denmark
    Atherosclerosis 206:17-30. 2009
    ....
  80. pmc Gene-centric association signals for lipids and apolipoproteins identified via the HumanCVD BeadChip
    Philippa J Talmud
    Centre for Cardiovascular Genetics, Department of Medicine, University College London, London WC1E 6JF, UK
    Am J Hum Genet 85:628-42. 2009
    ..These genes provide further insights into lipid metabolism and the likely effects of modifying the encoded targets therapeutically...
  81. ncbi Lipids, apolipoproteins, and their ratios in relation to cardiovascular events with statin treatment
    John J P Kastelein
    Academic Medical Center, Department of Vascular Medicine, University of Amsterdam, Amsterdam, The Netherlands
    Circulation 117:3002-9. 2008
    ....
  82. ncbi Microsomal triglyceride transfer protein -493T variant reduces IDL plus LDL apoB production and the plasma concentration of large LDL particles
    Björn Lundahl
    Atherosclerosis Research Unit, King Gustaf V Research Institute, Department of Medicine, Karolinska Institute, Karolinska Hospital, Stockholm, Sweden
    Am J Physiol Endocrinol Metab 290:E739-45. 2006
    ..Reduced direct production of LDL plus IDL appears to be related to lower plasma concentrations of large LDL particles...
  83. ncbi Potent reduction of apolipoprotein B and low-density lipoprotein cholesterol by short-term administration of an antisense inhibitor of apolipoprotein B
    John J P Kastelein
    Department of Vascular Medicine, Academic Medical Center, Meibergdreef 9, PO Box 22700, Room F4 159 2, 1100 DE Amsterdam, The Netherlands
    Circulation 114:1729-35. 2006
    ..In the present study, we describe the outcome of the first-in-humans study on the safety and efficacy of an antisense oligonucleotide inhibitor of apoB...
  84. pmc Association between hepatitis C virus and very-low-density lipoprotein (VLDL)/LDL analyzed in iodixanol density gradients
    Søren U Nielsen
    Liver Research Group, School of Clinical Medical Sciences, University of Newcastle, England
    J Virol 80:2418-28. 2006
    ..Immunoprecipitation analysis showed that ApoB remained associated with HCV after treatment of serum with deoxycholic acid or NP-40, whereas ApoE was removed from HCV with these detergents...
  85. pmc Expression of apolipoprotein B in the kidney attenuates renal lipid accumulation
    Marcin Krzystanek
    Department of Clinical Biochemistry, Rigshospitalet, DK 2100 Copenhagen
    J Biol Chem 285:10583-90. 2010
    ..The results suggest that mammalian kidney secretes apoB100-containing lipoproteins. One biological effect may be to dampen excess storage of triglycerides in proximal tubule cells...
  86. ncbi A population-based, cross-sectional comparison of lipid-related indexes for symptoms of atherosclerotic disease
    Stanley H Hsia
    Division of Endocrinology, Metabolism and Molecular Medicine, Charles R Drew University of Medicine and Science, Los Angeles, California, USA
    Am J Cardiol 98:1047-52. 2006
    ..The LDL/HDL cholesterol ratio was only significant for lean patients. In conclusion, these observations add to the published data suggesting that LDL cholesterol may not be the best target of lipid-lowering treatment strategies...
  87. doi Effect of a traditional Mediterranean diet on apolipoproteins B, A-I, and their ratio: a randomized, controlled trial
    Rosa Solà
    Human Nutrition Department, School of Medicine, University Rovira i Virgili, Reus, Spain
    Atherosclerosis 218:174-80. 2011
    ..Our aim was to assess the effect of a traditional Mediterranean diet (TMD) on apolipoproteins...
  88. pmc Improved efficacy for ezetimibe and rosuvastatin by attenuating the induction of PCSK9
    Brandon Ason
    Sirna Therapeutics Merck and Co Inc, San Francisco, CA 94158, USA
    J Lipid Res 52:679-87. 2011
    ..Taken together, these data provide evidence that PCSK9 inhibitors, in combination with current therapies, have the potential to achieve greater reductions in both serum cholesterol and triglycerides...
  89. pmc Hepatic insulin signaling regulates VLDL secretion and atherogenesis in mice
    Seongah Han
    Division of Molecular Medicine, Department of Medicine, Columbia University, 630 West 168th St, New York, New York 10032, USA
    J Clin Invest 119:1029-41. 2009
    ..These findings suggest a dual action of hepatic IR on lipoprotein levels, in which the ability to increase VLDL apoB and lipid secretion via AKT/GSK is offset by upregulation of Ldlr...
  90. doi Apolipoprotein B and non-high-density lipoprotein cholesterol are better risk markers for coronary artery disease than low-density lipoprotein cholesterol in hypertriglyceridemic metabolic syndrome patients
    Imen Boumaiza
    Department of Biochemistry, University Hospital Shaloul, Sousse, Tunisia
    Metab Syndr Relat Disord 8:515-22. 2010
    ....
  91. ncbi Plasma lipid profile and incident ischemic stroke: the Atherosclerosis Risk in Communities (ARIC) study
    Eyal Shahar
    Division of Epidemiology, University of Minnesota, 1300 South Second St, Suite 300, Minneapolis, MN 55454, USA
    Stroke 34:623-31. 2003
    ..The role of circulating lipids and lipoproteins in the pathogenesis of ischemic stroke remains uncertain despite 3 decades of research. We examined this issue in a large population-based cohort...
  92. doi Association of functional polymorphism of ApoB promoter with hepatitis C virus infection
    Chengliang Zhu
    The State Key Laboratory of Virology, College of Life Sciences and Chinese French Liver Disease Research Institute, Zhongnan Hospital, Wuhan University, Wuhan, PR China
    Clin Chim Acta 401:124-7. 2009
    ..ApoB promoter polymorphisms influence the levels of ApoB and LDL in blood. We investigated the correlations between ApoB promoter polymorphism and HCV infection...
  93. ncbi Obesity and atherogenic dyslipidemia
    Vaneeta Bamba
    Division of Endocrinology, Children s Hospital of Philadelphia, USA
    Gastroenterology 132:2181-90. 2007
    ..We also discuss the pathophysiology of low HDL cholesterol in obesity and the implications for cardiovascular disease risk...
  94. ncbi Oxidation of apolipoprotein B-containing lipoproteins and serum paraoxonase/arylesterase activities in major depressive disorder
    Asli Sarandol
    Department of Psychiatry, Uludag University Medical Faculty, 16059 Bursa, Turkey
    Prog Neuropsychopharmacol Biol Psychiatry 30:1103-8. 2006
    ..The findings of the present study suggest that: 1) antidepressant treatment might reduce serum paraoxonase activity/mass; 2) oxidation and oxidizability of apolipoprotein B-containing lipoproteins seem to be increased in MDD...
  95. ncbi The 9cis,11trans,13cis isomer of conjugated linolenic acid reduces apolipoprotein B100 secretion and triacylglycerol synthesis in HepG2 cells
    Keisuke Arao
    Department of Applied Biological Sciences, Saga University, Honjyo 1, Saga 840 8502, Japan
    Biosci Biotechnol Biochem 68:2643-5. 2004
    ..The uptake of (14)C-oleate into newly synthesized cellular triacylglycerol was also decreased by 9c,11t,13c-CLNA more than by alpha-LNA treatment. This is the first study to show the hypolipidemic effect of 9c,11t,13c-CLNA...
  96. ncbi Molecular diagnosis of hypobetalipoproteinemia: an ENID review
    Patrizia Tarugi
    Department of Biomedical Sciences, University of Modena e Reggio Emilia, Via Campi 287, I 41100 Modena, Italy
    Atherosclerosis 195:e19-27. 2007
    ..Inactivation of this enzyme is associated with an increased LDL uptake and hypobetalipoproteinemia. HBL carriers of PCSK9 mutations do not develop fatty liver disease...
  97. ncbi Eliminating atherogenesis in mice by switching off hepatic lipoprotein secretion
    Hsiao D Lieu
    Gladstone Institute of Cardiovascular Disease, San Francisco, CA 94141 9100, USA
    Circulation 107:1315-21. 2003
    ..We hypothesized that both the hypercholesterolemia and the susceptibility to atherosclerosis could be eliminated by switching off hepatic lipoprotein production...
  98. ncbi Very low density lipoprotein (VLDL) receptor-deficient mice have reduced lipoprotein lipase activity. Possible causes of hypertriglyceridemia and reduced body mass with VLDL receptor deficiency
    Hiroaki Yagyu
    Department of Medicine, Columbia University, New York, New York 10032, USA
    J Biol Chem 277:10037-43. 2002
    ..Therefore, the VLDLr is required for normal LpL regulation in vivo, and the disruption of VLDLr results in hypertriglyceridemia associated with decreased LpL activity...
  99. ncbi Microsomal triacylglycerol transfer protein is required for lumenal accretion of triacylglycerol not associated with ApoB, as well as for ApoB lipidation
    Agnes Kulinski
    Canadian Institutes for Health Research Group in Molecular and Cell Biology of Lipids, and the Department of Medicine, University of Alberta, Edmonton, Alberta T6G 2S2, Canada
    J Biol Chem 277:31516-25. 2002
    ....
  100. ncbi Breastmilk feeding and lipoprotein profile in adolescents born preterm: follow-up of a prospective randomised study
    Atul Singhal
    MRC Childhood Nutrition Research Centre, Institute of Child Health, London, UK
    Lancet 363:1571-8. 2004
    ..We tested the hypothesis that breastmilk feeding benefits the lipoprotein profile in adolescents born preterm, in whom randomisation to different diets at birth is feasible...
  101. ncbi Very-low-density lipoprotein assembly and secretion
    G S Shelness
    Department of Pathology, Wake Forest University School of Medicine, Winston Salem, North Carolina, USA
    Curr Opin Lipidol 12:151-7. 2001
    ..VLDL production is controlled primarily at the level of presecretory degradation. Recently, it was discovered that the LDL receptor modulates VLDL production through its interactions with nascent VLDL in the secretory pathway...

Research Grants93

  1. Development of CNS-targeted AAV vectors
    Miguel Esteves; Fiscal Year: 2009
    ..The proposed studies benefit from unique features of the scientific environment, subject populations, or employ useful collaborative arrangements. There is evidence of institutional support. ..
  2. MOLECULAR MECHANISMS OF OXIDATION OF LDL
    Sampath Parthasarathy; Fiscal Year: 1999
    ..He also proposes to generate antibodies against specific dicarboxylic acid containing phospholipids. He will then determine whether such antibodies react against epitopes in oxidized LDL, plasma and atherosclerotic plaques. ..
  3. APOLIPOPROTEIN B48 AND LIPOPROTEIN METABOLISM
    Lawrence Chan; Fiscal Year: 2002
    ..Thus, the overall project is highly relevant to lipid nutrient absorption and homeostasis. Significantly, it also provides important information on a newly described pathway in posttranscriptional gene regulation. ..
  4. APOLIPOPROTEIN B48 AND LIPOPROTEIN METABOLISM
    Lawrence Chan; Fiscal Year: 2000
    ..Thus, the overall project is highly relevant to lipid nutrient absorption and homeostasis. Significantly, it also provides important information on a newly described pathway in posttranscriptional gene regulation. ..
  5. APOLIPOPROTEIN B48 AND LIPOPROTEIN METABOLISM
    Lawrence Chan; Fiscal Year: 2003
    ..Thus, the overall project is highly relevant to lipid nutrient absorption and homeostasis. Significantly, it also provides important information on a newly described pathway in posttranscriptional gene regulation. ..
  6. APOLIPOPROTEIN B48 AND LIPOPROTEIN METABOLISM
    Lawrence Chan; Fiscal Year: 2002
    ..Thus, the overall project is highly relevant to lipid nutrient absorption and homeostasis. Significantly, it also provides important information on a newly described pathway in posttranscriptional gene regulation. ..
  7. APOLIPOPROTEIN B48 AND LIPOPROTEIN METABOLISM
    Lawrence Chan; Fiscal Year: 2004
    ..Thus, the overall project is highly relevant to lipid nutrient absorption and homeostasis. Significantly, it also provides important information on a newly described pathway in posttranscriptional gene regulation. ..
  8. APOLIPOPROTEIN B48 AND LIPOPROTEIN METABOLISM
    Lawrence Chan; Fiscal Year: 2001
    ..Thus, the overall project is highly relevant to lipid nutrient absorption and homeostasis. Significantly, it also provides important information on a newly described pathway in posttranscriptional gene regulation. ..
  9. NUTRITIONAL EFFECTS OF SUGARS ON LIVER LIPIDS
    CHARLES SPARKS; Fiscal Year: 1990
    ..Studies are important considering apo B and apo A-I lipoproteins are risk factors in atherogenesis...
  10. ASSEMBLY OF NASCENT PLASMA LIPOPROTEINS BY HEPATOCYTES
    Robert Hamilton; Fiscal Year: 1991
    ..Answers to these basic questions may indicate ways in which VLDL assembly and secretion can be regulated as a means of controlling the levels of atherogenic and antiatherogenic lipoproteins...
  11. ASSEMBLY PATHWAY OF VLDL--A THREE STEP PROCESS
    LARRY SWIFT; Fiscal Year: 2001
    ..Specific methods are spelled out in much greater detail in a separate section on specific methods. Both the rat and the cell culture experiments are very well defined as is the proposed time table for the studies. ..
  12. ASSEMBLY PATHWAY OF VLDL--A THREE STEP PROCESS
    LARRY SWIFT; Fiscal Year: 1999
    ..Specific methods are spelled out in much greater detail in a separate section on specific methods. Both the rat and the cell culture experiments are very well defined as is the proposed time table for the studies. ..
  13. ASSEMBLY PATHWAY OF VLDL--A THREE STEP PROCESS
    LARRY SWIFT; Fiscal Year: 2000
    ..Specific methods are spelled out in much greater detail in a separate section on specific methods. Both the rat and the cell culture experiments are very well defined as is the proposed time table for the studies. ..
  14. ApoB and ApoA-I Kinetics in the ApoB-67 Mutation
    Francine Welty; Fiscal Year: 2006
    ..The apoB-67 mutation may provide insights into mechanisms of low LDL-C and high HDL-C levels and new and better therapies to lower cholesterol. ..
  15. ApoB and ApoA-I Kinetics in the ApoB-67 Mutation
    Francine Welty; Fiscal Year: 2003
    ..The apoB-67 mutation may provide insights into mechanisms of low LDL-C and high HDL-C levels and new and better therapies to lower cholesterol. ..
  16. ApoB and ApoA-I Kinetics in the ApoB-67 Mutation
    Francine Welty; Fiscal Year: 2004
    ..The apoB-67 mutation may provide insights into mechanisms of low LDL-C and high HDL-C levels and new and better therapies to lower cholesterol. ..
  17. ApoB and ApoA-I Kinetics in the ApoB-67 Mutation
    Francine Welty; Fiscal Year: 2002
    ..The apoB-67 mutation may provide insights into mechanisms of low LDL-C and high HDL-C levels and new and better therapies to lower cholesterol. ..
  18. ApoB and ApoA-I Kinetics in the ApoB-67 Mutation
    Francine Welty; Fiscal Year: 2005
    ..The apoB-67 mutation may provide insights into mechanisms of low LDL-C and high HDL-C levels and new and better therapies to lower cholesterol. ..
  19. REGULATION OF APOB SECRETION IN INBRED MOUSE STRAINS
    Li Shin Huang; Fiscal Year: 2009
    ..It will also be a potential target for drug discovery and pharmacological intervention in hyperlipidemic patients in the general population. ..
  20. REGULATION OF APOB SECRETION IN INBRED MOUSE STRAINS
    Li Shin Huang; Fiscal Year: 2007
    ..It will also be a potential target for drug discovery and pharmacological intervention in hyperlipidemic patients in the general population. [unreadable] [unreadable] [unreadable]..
  21. REGULATION OF APOB SECRETION IN INBRED MOUSE STRAINS
    Li Shin Huang; Fiscal Year: 2006
    ..It will also be a potential target for drug discovery and pharmacological intervention in hyperlipidemic patients in the general population. [unreadable] [unreadable] [unreadable]..
  22. REGULATION OF APOB SECRETION IN INBRED MOUSE STRAINS
    Li Shin Huang; Fiscal Year: 2005
    ..It will also be a potential target for drug discovery and pharmacological intervention in hyperlipidemic patients in the general population. ..
  23. INTESTINAL LIPOPROTEINS IN THE NEONATE
    Dennis Black; Fiscal Year: 2000
    ..Results of these studies will ultimately guide the provision of dietary lipid to the neonate in a form which will optimize lipoprotein and apolipoprotein synthesis and secretion. ..
  24. INTESTINAL LIPOPROTEINS IN THE NEONATE
    Dennis Black; Fiscal Year: 1999
    ..Results of these studies will ultimately guide the provision of dietary lipid to the neonate in a form which will optimize lipoprotein and apolipoprotein synthesis and secretion. ..
  25. INTESTINAL LIPOPROTEINS IN THE NEONATE
    Dennis Black; Fiscal Year: 2001
    ..Results of these studies will ultimately guide the provision of dietary lipid to the neonate in a form which will optimize lipoprotein and apolipoprotein synthesis and secretion. ..
  26. LIPOGENESIS & LIPOPROTEIN COMPLICATIONS OF HIV THERAPY
    David Hui; Fiscal Year: 2000
    ..Collaboration with the companion grant will facilitate the evaluation of dietary and/or therapeutic manipulations as treatment to suppress the adverse effects of PI. ..
  27. LIPOGENESIS & LIPOPROTEIN COMPLICATIONS OF HIV THERAPY
    David Hui; Fiscal Year: 2001
    ..Collaboration with the companion grant will facilitate the evaluation of dietary and/or therapeutic manipulations as treatment to suppress the adverse effects of PI. ..
  28. LIPOGENESIS & LIPOPROTEIN COMPLICATIONS OF HIV THERAPY
    David Hui; Fiscal Year: 2003
    ..Collaboration with the companion grant will facilitate the evaluation of dietary and/or therapeutic manipulations as treatment to suppress the adverse effects of PI. ..
  29. LIPOGENESIS & LIPOPROTEIN COMPLICATIONS OF HIV THERAPY
    David Hui; Fiscal Year: 2004
    ..Collaboration with the companion grant will facilitate the evaluation of dietary and/or therapeutic manipulations as treatment to suppress the adverse effects of PI. ..
  30. LIPOGENESIS & LIPOPROTEIN COMPLICATIONS OF HIV THERAPY
    David Hui; Fiscal Year: 2002
    ..Collaboration with the companion grant will facilitate the evaluation of dietary and/or therapeutic manipulations as treatment to suppress the adverse effects of PI. ..
  31. EDITING OF APOLIPOPROTEIN-B MRNA
    DONNA DRISCOLL; Fiscal Year: 2003
    ..The successful pursuit of these aims should provide insight into the mechanism of apo-B mRNA editing and the function of ACF. ..
  32. EDITING OF APOLIPOPROTEIN-B MRNA
    DONNA DRISCOLL; Fiscal Year: 2004
    ..The successful pursuit of these aims should provide insight into the mechanism of apo-B mRNA editing and the function of ACF. ..
  33. EDITING OF APOLIPOPROTEIN-B MRNA
    DONNA DRISCOLL; Fiscal Year: 2001
    ..The successful pursuit of these aims should provide insight into the mechanism of apo-B mRNA editing and the function of ACF. ..
  34. FORMATION AND SECRETION OF INTESTINAL LIPOPROTEINS
    Patrick Tso; Fiscal Year: 1992
    ..SPECIFIC AIM 4. We will determine the molecular mechanisms responsible for the pre-translational and translational regulation of apo A-IV MRNA in the small intestine after L-81 treatment...
  35. EDITING OF APOLIPOPROTEIN-B MRNA
    DONNA DRISCOLL; Fiscal Year: 2002
    ..The successful pursuit of these aims should provide insight into the mechanism of apo-B mRNA editing and the function of ACF. ..
  36. APOLIPOPROTEIN B EXPRESSION STUDIES
    MacRae Linton; Fiscal Year: 1993
    ....
  37. METABOLISM AND GENETICS OF HYPOBETALIPOPROTEINEMIA
    Gustav Schonfeld; Fiscal Year: 2001
    ..In all these families it has been documented that the affected subjects do not have any evidence of truncated for of apoB. ..
  38. METABOLISM AND GENETICS OF HYPOBETALIPOPROTEINEMIA
    Gustav Schonfeld; Fiscal Year: 2002
    ..In all these families it has been documented that the affected subjects do not have any evidence of truncated for of apoB. ..
  39. METABOLISM AND GENETICS OF HYPOBETALIPOPROTEINEMIA
    Gustav Schonfeld; Fiscal Year: 1999
    ..In all these families it has been documented that the affected subjects do not have any evidence of truncated for of apoB. ..
  40. METABOLISM AND GENETICS OF HYPOBETALIPOPROTEINEMIA
    Gustav Schonfeld; Fiscal Year: 2000
    ..In all these families it has been documented that the affected subjects do not have any evidence of truncated for of apoB. ..
  41. APOLIPOPROTEIN B48 AND LIPOPROTEIN METABOLISM
    Lawrence Chan; Fiscal Year: 1999
    ..The project may provide important information related to lipoprotein metabolism and atherosclerosis and a novel pathway involved in the posttranscriptional regulation of gene expression. ..
  42. MECHANISM OF APOLIPOPROTEIN B-48 BIOGENESIS
    Lawrence Chan; Fiscal Year: 1993
    ..The proposed work will shed light on this process, which also has profound implications for general cell and molecular biology...
  43. MECHANISM OF APOLIPOPROTEIN B-48 BIOGENESIS
    Lawrence Chan; Fiscal Year: 1991
    ..The proposed work will shed light on this process, which also has profound implications for general cell and molecular biology...
  44. METABOLIC REGULATION OF APOLIPOPROTEIN B MRNA EDITING
    Harold Smith; Fiscal Year: 1999
    ..Through the proposed research, it should be possible to determine which proteins and interactions are necessary and sufficient for editing to occur, and which factors and interactions are involved in modulating the level of editing. ..
  45. EDITING OF APOLIPOPROTEIN-B MRNA
    DONNA DRISCOLL; Fiscal Year: 1999
    ..Other mRNA targets of the enzyme or its subunits will be identified using tissue-specific combinatorial RNA shape libraries. The results of our studies will provide insight into the mechanism of apo-B mRNA editing. ..
  46. ENTEROHEPATIC LIPID FLUX AND APOPROTEIN BIOSYNTHESIS.
    NICHOLAS DAVIDSON; Fiscal Year: 2003
    ..The investigators will examine the hypothesis in the current application that there are other cytidine deaminases, related to apobec-1, with functions involving site-specific RNA interactions. ..
  47. GENETIC EPIDEMIOLOGY OF ELEVATED APOB LEVEL
    GAIL JARVIK; Fiscal Year: 1999
    ..Aim 5. To refine the position of the apolipoprotein B elevating level gene(s). Aim 6. Subsequent work to identify the locus if positive evidence of linkage to a strong candidate gene region is obtained. ..
  48. ENTEROHEPATIC LIPID FLUX AND APOPROTEIN BIOSYNTHESIS.
    NICHOLAS DAVIDSON; Fiscal Year: 2002
    ..The investigators will examine the hypothesis in the current application that there are other cytidine deaminases, related to apobec-1, with functions involving site-specific RNA interactions. ..
  49. ENTEROHEPATIC LIPID FLUX AND APOPROTEIN BIOSYNTHESIS.
    NICHOLAS DAVIDSON; Fiscal Year: 2004
    ..The investigators will examine the hypothesis in the current application that there are other cytidine deaminases, related to apobec-1, with functions involving site-specific RNA interactions. ..
  50. ENTEROHEPATIC LIPID FLUX AND APOPROTEIN BIOSYNTHESIS.
    NICHOLAS DAVIDSON; Fiscal Year: 2001
    ..The investigators will examine the hypothesis in the current application that there are other cytidine deaminases, related to apobec-1, with functions involving site-specific RNA interactions. ..
  51. ENTEROHEPATIC LIPID FLUX AND APOPROTEIN BIOSYNTHESIS.
    NICHOLAS DAVIDSON; Fiscal Year: 2006
    ..The investigators will examine the hypothesis in the current application that there are other cytidine deaminases, related to apobec-1, with functions involving site-specific RNA interactions. ..
  52. ENTEROHEPATIC LIPID FLUX AND APOPROTEIN BIOSYNTHESIS.
    NICHOLAS DAVIDSON; Fiscal Year: 2007
    ..We will examine the hypothesis in the current application that there are other cytidine deaminases, related to apobec-1, with functions involving site-specific RNA interactions. ..
  53. ENTEROHEPATIC LIPID FLUX AND APOPROTEIN BIOSYNTHESIS.
    NICHOLAS DAVIDSON; Fiscal Year: 2009
    ..We will examine the hypothesis in the current application that there are other cytidine deaminases, related to apobec-1, with functions involving site-specific RNA interactions. ..
  54. ENTEROHEPATIC LIPID FLUX AND APOPROTEIN BIOSYNTHESIS.
    NICHOLAS DAVIDSON; Fiscal Year: 2000
    ..The investigators will examine the hypothesis in the current application that there are other cytidine deaminases, related to apobec-1, with functions involving site-specific RNA interactions. ..
  55. CORE--CHEMICAL AND BIOCHEMICAL TECHNIQUES
    Mary Walsh; Fiscal Year: 2004
    ..Graduate students, post-doctoral fellows, and technicians are trained in analytic procedures by Core C staff to ensure uniformity and consistency within the Program Project. ..
  56. STEROL METABOLISM AND HUMAN MONONUCLEAR CELL FUNCTION
    Peter Lipsky; Fiscal Year: 1990
    ..lipoprotein classes including LDL, by chemical modification of lipoproteins to prevent binding of the apolipoproteins B and E (apo-B and apo-E) to the receptor and by the use of monoclonal antibodies directed against the ..
  57. IMPACT OF GENETIC ALTERATIONS ON LIPOPROTEIN METABOLISM
    THOMAS INNERARITY; Fiscal Year: 1992
    ..In addition, animal models with gene defects that cause specific lipoprotein disorders will be useful for testing therapeutic interventions...
  58. Avoiding toxicity associated with MTP ablation
    M Mahmood Hussain; Fiscal Year: 2012
    ..These studies may lead to new therapeutic modalities for the treatment of various hyperlipidemias and have immediate potential for translational use. ..
  59. REGULATION OF APOB SECRETION IN INBRED MOUSE STRAINS
    Li Shin Huang; Fiscal Year: 2000
    ..A BAC contig containing the critical interval will be analyzed and transcripts identified. Allelic variants for the candidate gene will be identified and tested for their functional significance. ..
  60. FISH OIL, LIPOPROTEINS AND ATHERIOGENESIS
    Dong Kim; Fiscal Year: 1990
    ..In the vitro studies we shall investigate and compare the effects of specific lipoprotein fractions on: (1) cell proliferation, (2) cell death and (3) uptake of lipid...
  61. ENTEROHEPATIC LIPID FLUX AND APOPROTEIN BIOSYNTHESIS
    NICHOLAS DAVIDSON; Fiscal Year: 1999
    ..Taken together, this approach should allow elucidation of the molecular mechanisms underlying this novel pathway for gene regulation in the mammalian small intestine. ..
  62. REGULATION OF APOB SECRETION IN INBRED MOUSE STRAINS
    Li Shin Huang; Fiscal Year: 2002
    ..A BAC contig containing the critical interval will be analyzed and transcripts identified. Allelic variants for the candidate gene will be identified and tested for their functional significance. ..
  63. REGULATION OF APOB SECRETION IN INBRED MOUSE STRAINS
    Li Shin Huang; Fiscal Year: 2001
    ..A BAC contig containing the critical interval will be analyzed and transcripts identified. Allelic variants for the candidate gene will be identified and tested for their functional significance. ..
  64. MECHANISM OF PI-RELATED DYSLIPIDEMIA AND ATHEROSCLEROSIS
    Daniel Rader; Fiscal Year: 2000
    ..These studies will provide novel insights into the mechanisms of PI-associated dyslipidemia and atherosclerosis. ..
  65. MECHANISM OF PI-RELATED DYSLIPIDEMIA AND ATHEROSCLEROSIS
    Daniel Rader; Fiscal Year: 2001
    ..These studies will provide novel insights into the mechanisms of PI-associated dyslipidemia and atherosclerosis. ..
  66. MECHANISM OF PI-RELATED DYSLIPIDEMIA AND ATHEROSCLEROSIS
    Daniel Rader; Fiscal Year: 2001
    ..These studies will provide novel insights into the mechanisms of PI-associated dyslipidemia and atherosclerosis. ..
  67. MECHANISM OF PI-RELATED DYSLIPIDEMIA AND ATHEROSCLEROSIS
    Daniel Rader; Fiscal Year: 2002
    ..These studies will provide novel insights into the mechanisms of PI-associated dyslipidemia and atherosclerosis. ..
  68. MECHANISM OF PI-RELATED DYSLIPIDEMIA AND ATHEROSCLEROSIS
    Daniel Rader; Fiscal Year: 2004
    ..These studies will provide novel insights into the mechanisms of PI-associated dyslipidemia and atherosclerosis. ..
  69. MECHANISM OF PI-RELATED DYSLIPIDEMIA AND ATHEROSCLEROSIS
    Daniel Rader; Fiscal Year: 2004
    ..These studies will provide novel insights into the mechanisms of PI-associated dyslipidemia and atherosclerosis. ..
  70. EFFECTS OF DIETARY FATS ON LIPOPROTEIN METABOLISM
    ERNST SCHAEFER; Fiscal Year: 1990
    ..4) assess the effect of this diet on blood pressure...
  71. MECHANISM OF PI-RELATED DYSLIPIDEMIA AND ATHEROSCLEROSIS
    Daniel Rader; Fiscal Year: 2003
    ..These studies will provide novel insights into the mechanisms of PI-associated dyslipidemia and atherosclerosis. ..
  72. MECHANISM OF PI-RELATED DYSLIPIDEMIA AND ATHEROSCLEROSIS
    Daniel Rader; Fiscal Year: 2002
    ..These studies will provide novel insights into the mechanisms of PI-associated dyslipidemia and atherosclerosis. ..
  73. ENTEROHEPATIC LIPID FLUX AND APOPROTEIN BIOSYNTHESIS
    NICHOLAS DAVIDSON; Fiscal Year: 2010
    ....
  74. APOLIPOPROTEIN E IN CHOLESTEROL TRANSPORT AND METABOLISM
    ROBERT PITAS; Fiscal Year: 1990
    ..Together, these studies will help elucidate the role of apo-E in normal nervous tissue and in nerve regeneration...
  75. LOW DENSITY LIPOPROTEIN AND INFLAMMATION
    Robert Terkeltaub; Fiscal Year: 1991
    ....
  76. LOW DENSITY LIPOPROTEIN AND INFLAMMATION
    Robert Terkeltaub; Fiscal Year: 1993
    ....
  77. METABOLIC REGULATION OF APOLIPOPROTEIN B MRNA EDITING
    Harold Smith; Fiscal Year: 2003
    ....
  78. METABOLIC REGULATION OF APOLIPOPROTEIN B MRNA EDITING
    Harold Smith; Fiscal Year: 2001
    ....
  79. METABOLIC REGULATION OF APOLIPOPROTEIN B MRNA EDITING
    Harold Smith; Fiscal Year: 2000
    ....
  80. METABOLIC REGULATION OF APOLIPOPROTEIN B MRNA EDITING
    Harold Smith; Fiscal Year: 2002
    ....
  81. METABOLIC REGULATION OF APO B MRNA EDITING
    Harold Smith; Fiscal Year: 1993
    ..Moreover, the information obtained in these studies will be important for evaluating the generic properties of mRNA editing and identifying other mRNAs which might serve as editing substrates...
  82. INTESTINAL SPECIFIC APO B: ASSEMBLY AND PROCESSING
    VODEK SASAK; Fiscal Year: 1990
    ..This should contribute to the understanding of intestinal lipid metabolism and determination of metabolic defects in various lipid disorders...
  83. METABOLIC REGULATION OF APO B MRNA EDITING
    Harold Smith; Fiscal Year: 1992
    ..Moreover, the information obtained in these studies will be important for evaluating the generic properties of mRNA editing and identifying other mRNAs which might serve as editing substrates...